Chinese biopharmaceutical companies are increasingly focusing on obesity treatments, leveraging strong domestic demand and supportive regulatory policies to drive innovation and target international markets. This shift marks a significant development in the global race to address metabolic diseases such as obesity and type 2 diabetes.
In 2025, AstraZeneca agreed to pay up to $18.5 billion for rights to eight obesity and diabetes programs from Chinese drug maker CSPC, including a once-monthly injectable medication. Meanwhile, Kailera Therapeutics, a U.S.-based firm with obesity assets licensed from Chinese pharmaceutical company Jiangsu Hengrui, raised $625 million through an initial public offering in April. Such deals underscore China’s growing influence in this therapeutic area.
The backdrop for this surge is China’s rising obesity rates. The country’s National Health Commission reported that more than half of Chinese adults are overweight or obese, warning that this number could climb to over 70 percent by 2030 if current trends continue. This public health challenge has encouraged pharmaceutical firms to prioritize the development of effective treatments.
Historically, obesity drugs were seen as commercially unviable due to safety concerns and limited reimbursement coverage, often regarded as lifestyle rather than medical treatments. However, the success of drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, coupled with China’s 2024–26 weight management campaign, has shifted both clinical and commercial perspectives. These developments have provided regulatory support and infrastructure for domestic drug development.
A milestone for the sector came in June 2025 when Chinese regulators approved Innovent Biologics’ mazdutide, a dual GLP-1/glucagon receptor agonist, for chronic weight management. This marked a departure from seeing GLP-1 agents merely as diabetes medications with secondary weight loss effects, toward recognizing obesity as a distinct therapeutic target.
Industry experts differ on whether China’s efforts represent true innovation or rapid catch-up. Justin Wang, head of L.E.K. Consulting’s China operation, argues that Chinese-developed drugs demonstrate increasing differentiation, including advancements in multi-agonist therapies, long-acting and oral formulations, as well as cost reductions. Nevertheless, he cautions that the crowded market will likely reward only select candidates.
Chinese drugs face challenges similar to their Western counterparts, such as concerns about high costs, lifelong treatment requirements, and weight regain after discontinuation. The expiration of Novo Nordisk’s semaglutide patent in China this year has intensified competition, with more than a dozen domestic generics in advanced development. Market prices have already declined amid this crowded landscape.
Beyond generics, some Chinese companies are pursuing novel approaches. Jiangsu Hengrui’s oral compound HRS-7535 demonstrated approximately 11 percent average weight loss over 44 weeks in phase three trials. Meanwhile, Hua Medicine’s dorzagliatin targets glucokinase, a glucose-sensing enzyme, addressing the underlying causes of diabetes rather than only appetite suppression. Hua Medicine’s drug secured approval in Hong Kong earlier this year, with further clinical development ongoing in the United States.
Experts emphasize that pharmaceutical solutions alone are insufficient without comprehensive healthcare infrastructure. China’s new obesity treatment guidelines recognize the condition as a disease requiring coordinated multidisciplinary care. Clinical specialists stress the continuing importance of lifestyle interventions alongside pharmacotherapy to manage weight and metabolic health in the long term.
Looking ahead, Chinese firms aim to validate their therapies internationally. Success abroad will depend on meeting stringent regulatory standards from agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, as well as navigating potential hurdles like proposed national security reviews of licensing deals. Despite these challenges, analysts remain optimistic about the future impact of Chinese innovations in obesity treatment.